铁与铁载体在感染中的作用及铁载体抗生素的研发
本文综述了细菌获取铁的营养机制,包括铁载体介导的主动转运系统和直接摄取宿主铁结合蛋白,并讨论了利用该系统的铁载体偶联抗生素的研发进展与挑战,其中头孢地尔已进入1至3期临床试验。
要点
- 细菌通过铁载体及TonB-ExbBD能量转导系统等主动转运机制从宿主环境获取铁。
- 铁载体按铁螯合基团化学性质分为儿茶酚、异羟肟酸、α-羟基羧酸或混合型。
- 铁载体偶联抗生素对多重耐药革兰阴性菌体外活性高,但部分候选药物因适应性耐药、体内疗效不一致或副作用而停止开发。
核心结论
- 铁是细菌生长、复制和代谢的必需营养,细菌进化出多种机制从宿主环境摄取铁,铁载体偶联抗生素可利用该转运系统治疗革兰阴性菌感染。
研究设计与样本
- 本文为综述,讨论铁摄取机制及铁载体模拟抗生素设计与应用的挑战。
主要发现
- 细菌铁摄取依赖铁载体、外膜铁载体受体、TonB-ExbBD能量转导蛋白及内膜转运蛋白组成的主动转运系统。
- 部分细菌表达宿主铁结合蛋白的外膜受体,直接从中提取铁并转运入细菌胞质。
- 铁载体是几乎所有细菌种属产生和释放的小分子,按铁螯合基团化学性质分类。
- 铁载体偶联抗生素对病原性多重耐药菌体外活性高,但部分候选药物因暴露期间出现适应性耐药、缺乏一致的体内疗效或宿主副作用而停止开发。
- 头孢地尔结构优化后已推进并开展了1至3期临床试验。
临床怎么用
- 铁载体偶联抗生素利用细菌铁转运系统,为多重耐药革兰阴性菌感染提供潜在治疗选择。
- 开发此类药物需关注适应性耐药、体内疗效一致性和宿主副作用等挑战。
局限性
- 摘要未报告具体研究数据、样本量或统计值,相关结论基于综述性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Iron is an essential nutrient for bacterial growth, replication, and metabolism. Humans store iron bound to various proteins such as hemoglobin, haptoglobin, transferrin, ferritin, and lactoferrin, limiting the availability of free iron for pathogenic bacteria. However, bacteria have developed various mechanisms to sequester or scavenge iron from the host environment. Iron can be taken up by means of active transport systems that consist of bacterial small molecule siderophores, outer membrane siderophore receptors, the TonB-ExbBD energy-transducing proteins coupling the outer and the inner membranes, and inner membrane transporters. Some bacteria also express outer membrane receptors for iron-binding proteins of the host and extract iron directly from these for uptake. Ultimately, iron is acquired and transported into the bacterial cytoplasm. The siderophores are small molecules produced and released by nearly all bacterial species and are classified according to the chemical nature of their iron-chelating group (ie, catechol, hydroxamate, α-hydroxyl-carboxylate, or mixed types). Siderophore-conjugated antibiotics that exploit such iron-transport systems are under development for the treatment of infections caused by gram-negative bacteria. Despite demonstrating high in vitro potency against pathogenic multidrug-resistant bacteria, further development of several candidates had stopped due to apparent adaptive resistance during exposure, lack of consistent in vivo efficacy, or emergence of side effects in the host. However, cefiderocol, with an optimized structure, has advanced and has been investigated in phase 1 to 3 clinical trials. This article discusses the mechanisms implicated in iron uptake and the challenges associated with the design and utilization of siderophore-mimicking antibiotics.
引用
- Page MGP. The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics. Clin Infect Dis. 2019. PMID: 31724044. doi:10.1093/cid/ciz825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。